Almonertinib Plus Metronomic Oral Vinorelbine

NCT05663177 · clinicaltrials.gov ↗

UNKNOWN

Status

40

Enrollment

OTHER_GOV

Sponsor class

Conditions

EGFR
NSCLC
Third-generation TKI

Interventions

DRUG: Almonertinib and metronomic oral vinorelbine

Sponsor

Fujian Cancer Hospital